TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06416254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibre-enriched diet
Description: The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
Study: NCT06431230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard high-intensity interval training
Description: The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: plyometric high-intensity interval training
Description: The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
Study: NCT05351242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermotherapy/sauna bath
Description: Thermotherapy/sauna bath
Study: NCT03885141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem or Placebo if there is a wake up during the night
Study: NCT06112951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
Study: NCT05365633

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empowerment activity-enhanced tobacco cessation assistance
Description: Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and provide COVID-19 risk-reduction options (e.g., remote or masked outdoor activities). Examples are: (i) running tobacco-free Pride events that occur in Jun and Oct in OK; (ii) organizing a virtual SGM town hall to inform the OK State Plan on Aging; (iii) SGM-relevant legislative phone banking (e.g., regarding transgender student participation in school athletics); and (iv) follow-up surveying of Freedom OK's name and gender marker change clinic72 participants.
Study: NCT06024044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization Training
Description: The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients.
Study: NCT06135155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT06383468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: 300mg Q2W subcutaneous injection thereafter until week 50.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AK120
Description: 300mg Q2W subcutaneous injection thereafter until week 50.
Study: NCT04906057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Aerobic Exercise (FE)
Description: High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary Aerobic Exercise (VE)
Description: Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
Study: NCT06071481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution
Description: 2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution
Description: 2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
Study: NCT04896567

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cell isolation
Description: Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
Study: NCT05792852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
Study: NCT06043895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFaith CV
Description: The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
Study: NCT05273203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIM-1
Description: A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIM-2
Description: A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIM-3
Description: A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
Study: NCT05032131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSVF
Description: Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
Study: NCT06376201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B cholesterol-sulfate complex for injection
Description: Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition).
Study: NCT04858516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib and exemestane plus trastuzumab and pyrotinib
Description: Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
Study: NCT05191615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job crafting training
Description: Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist.
Study: NCT05046418

Intervention type: OTHER
Intervention: Hypoallergenic formula containing synbiotics
Description: An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
Study: NCT06207734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor Palbociclib
Description: Continuation of CDK4/6 inhibitor Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor Palbociclib
Description: Discontinuation of CDK4/6 inhibitor Palbociclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor -Palbociclib
Description: Continuation of CDK4/6 inhibitor -Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor -Palbociclib
Description: Discontinuation of CDK4/6 inhibitor -Palbociclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor Abemaciclib
Description: Continuation of CDK4/6 inhibitor Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor Abemaciclib
Description: Discontinuation of CDK4/6 inhibitor Abemaciclib
Study: NCT06013189

Intervention type: OTHER
Intervention: Gas Flow Adjustment
Description: Decreased gas flow causes PaCO2 to elevate and prevents alkalosis

Intervention type: OTHER
Intervention: Gas Flow Adjustment
Description: Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
Study: NCT06065891

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PALN resection
Description: Resection of paraaortic lymph nodes in pancreatic cancer
Study: NCT06481566

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative body radiotherapy
Description: The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
Study: NCT04867460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided venous access
Description: Access of the axillary vein using ultrasound guidance.
Study: NCT05245188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 1
Description: 11.3 glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 2
Description: 8.84 glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 3
Description: 4.24 glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 4
Description: 4.36 glucose
Study: NCT06463054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Group Training
Description: The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
Study: NCT04844528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: oral nicotinamide 500 mg twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
Study: NCT06206811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD-07656
Description: innate immune modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD-07656
Description: innate immune modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD-07656
Description: innate immune modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD-07656
Description: innate immune modulator
Study: NCT04969198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
Description: Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
Study: NCT06020755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200mg q2w intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous
Study: NCT05501795

Intervention type: DEVICE
Intervention: WaveLight® FS200 femtosecond laser
Description: Flap creation with the WaveLight® FS200 femtosecond laser
Study: NCT05023811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]RIST4271
Description: \[14C\]RIST4271 oral solution
Study: NCT06172764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements along with behavioral modification
Description: Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Topical fluoride application and Vitamin D supplements along with behavioral modification
Description: Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Topical fluoride application along with behavioral modification
Description: Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.
Study: NCT05128877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation techniques
Description: Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
Study: NCT06449807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: crossover point intensity exercise
Description: crossover point intensity exercise
Study: NCT04754347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Aided Detection device
Description: The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
Study: NCT06583551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myorel
Description: Metacarbamol (380mg), paracetamol (300mg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
Study: NCT06583421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week MVPA intervention
Description: The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
Study: NCT04768465

Intervention type: DRUG
Intervention: Pyridostigmine, Prednisone, Tacrolimus
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.

Intervention type: DRUG
Intervention: Pyridostigmine, Tacrolimus
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
Study: NCT05925023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
Study: NCT05609955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MgSO4
Description: The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
Study: NCT05716204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High force lateral distraction
Description: High force lateral distraction on the affected hip.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo distraction group
Description: Placebo lateral distraction on the affected hip.
Study: NCT04788056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal Subpectoral Plane Block
Description: Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Parasternal Subpectoral Plane Block
Description: Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.